Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. Materials and Methods Safety data were collected prospectively and we retrospectively collected efficacy data from the five French centres that participated in the Eribulin E7389-G000-398 expanded access program. Our main objectives were exploration of safety and analysis of eribulin efficacy (progression- free survival [PFS] and overall survival [OS]) according to sensitivity to the last microtubule-inhibiting agent administered. Results Median eribulin treatment duration was 3.3 months for the 250 patients included in this prospective single-arm study. Two hundreds and thirty-nine patients (95.6%) experienced an adverse event (AE) related to treatment including 129 (51.6%) with grade 3 AEs. The most frequently observed toxicities were cytopenias (59.6% of included patients), gastrointestinal disorders (59.2%), and asthenia (56.4%). The most frequent grade 3-4 AE was neutropenia (37.2% with 4.8% febrile neutropenia). Median PFS and OS were 4.6 and 11.8 months, respectively. Patients classified as responders to the last microtubule-inhibiting therapy had a longer OS (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.51 to 0.94; p=0.017), and tended to display a better PFS (HR, 0.78; 95% CI, 0.58 to 1.04; p=0.086). OS improvement was still significant in multivariate analysis (adjusted HR, 0.53; 95% CI, 0.35 to 0.79; p=0.002). Conclusion This work based on a prospective study suggests that identification of patients likely to be more sensitive to eribulin could be based on their previous response to microtubules inhibitors.
Abstract
Purpose Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. Materials and Methods Safety data were collected prospectively and we retrospectively collected efficacy data from the five French centres that participated in the Eribulin E7389-G000-398 expanded access program. Our main objectives were exploration of safety and analysis of eribulin efficacy (progression- free survival [PFS] and overall survival [OS]) according to sensitivity to the last microtubule-inhibiting agent administered. Results Median eribulin treatment duration was 3.3 months for the 250 patients included in this prospective single-arm study. Two hundreds and thirty-nine patients (95.6%) experienced an adverse event (AE) related to treatment including 129 (51.6%) with grade 3 AEs. The most frequently observed toxicities were cytopenias (59.6% of included patients), gastrointestinal disorders (59.2%), and asthenia (56.4%). The most frequent grade 3-4 AE was neutropenia (37.2% with 4.8% febrile neutropenia). Median PFS and OS were 4.6 and 11.8 months, respectively. Patients classified as responders to the last microtubule-inhibiting therapy had a longer OS (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.51 to 0.94; p=0.017), and tended to display a better PFS (HR, 0.78; 95% CI, 0.58 to 1.04; p=0.086). OS improvement was still significant in multivariate analysis (adjusted HR, 0.53; 95% CI, 0.35 to 0.79; p=0.002). Conclusion This work based on a prospective study suggests that identification of patients likely to be more sensitive to eribulin could be based on their previous response to microtubules inhibitors.
참고문헌 (29)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Cardoso F, "3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)", Ann Oncol, 28, pp.3111~ (2017)
- Baselga J, "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer", N Engl J Med, 366, pp.109~119 (2012)
- Geyer CE, "Lapatinib plus capecitabine for HER2-positive advanced breast cancer", N Engl J Med, 355, pp.2733~2743 (2006)
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Verma S, "Trastuzumab emtansine for HER2-positive advanced breast cancer", N Engl J Med, 367, pp.1783~1791 (2012)
- Baselga J, "Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer", N Engl J Med, 366, pp.520~529 (2012)
- Cristofanilli M, "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial", Lancet Oncol, 17, pp.425~439 (2016)
- Finn RS, "The cyclin-dependent kinase 4", 6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1, Lancet Oncol, pp.2015, 16[DOI]
- Hortobagyi GN, "Ribociclib as first-line therapy for HR-positive, advanced breast cancer", N Engl J Med, 375, pp.1738~1748 (2016)
- Twelves C, "Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer", Crit Rev Oncol Hematol, 100, pp.74~87 (2016)
- Kok VC, "Eribulin in the management of advanced breast cancer: implications of current research findings", Breast Cancer (Auckl), 9, pp.109~115 (2015)
- Cortes J, "Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study", Lancet, 377, pp.914~923 (2011)
- Kaufman PA, "Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane", J Clin Oncol, 33, pp.594~601 (2015)
- Pivot X, "Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy", Ann Oncol, 27, pp.1525~1531 (2016)
- Aogi K, "A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer", Ann Oncol, 23, pp.1441~1448 (2012)
- Inoue K, "Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had welldefined taxane resistance", Breast Cancer Res Treat, 157, pp.295~305 (2016)
- Vahdat LT, "Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane", J Clin Oncol, 27, pp.2954~2961 (2009)
- Dell'Ova M, "Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study", BMC Cancer, 15, pp.659~ (2015)
- Aftimos P, "Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial", Eur J Cancer, 60, pp.117~124 (2016)
- Jimeno A, "Eribulin: rediscovering tubulin as an anticancer target", Clin Cancer Res, 15, pp.3903~3905 (2009)
- McBride A, "Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer", Am J Health Syst Pharm, 69, pp.745~755 (2012)
- Twelves C, "Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies", Breast Cancer Res Treat, 148, pp.553~561 (2014)
- Schwartz LH, "RECIST 1.1-Update and clarification: from the RECIST committee", Eur J Cancer, 62, pp.132~137 (2016)
- Wahl RL, "From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors", J Nucl Med, 50(Suppl 1), pp.122S~150S (2009)
- von Elm E, "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies", Prev Med, 45, pp.247~251 (2007)
- Dufresne A, "Impact of chemotherapy beyond the first line in patients with metastatic breast cancer", Breast Cancer Res Treat, 107, pp.275~279 (2008)
- Zelek L, "Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma", Cancer, 92, pp.2267~2272 (2001)
- Lopes G, "A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer", Breast Cancer Res Treat, 137, pp.187~193 (2013)